Literature DB >> 6223818

Studies on 18F-labeled pyrimidines. Tumor uptakes of 18F-5-fluorouracil, 18F-5-fluorouridine, and 18F-5-fluorodeoxyuridine in animals.

Y Abe, H Fukuda, K Ishiwata, S Yoshioka, K Yamada, S Endo, K Kubota, T Sato, T Matsuzawa, T Takahashi, T Ido.   

Abstract

Three 18F-labeled pyrimidines, 18F-5-fluorouridine (18F-5-FUR), 18F-5-fluorouracil (18F-5-FU), and 18F-5-fluorodeoxyuridine (18F-5-FdUR), were examined regarding tissue distribution and tumor uptake in ascitic hepatoma AH109A-bearing rats. The differential absorption ratios of tumors of 18F-5-FUR, 18F-5-FU, and 18F-5-FdUR were 0.75 +/- 0.21, 0.92 +/- 0.15, and 0.96 +/- 0.24 at 30 min, and 0.37 +/- 0.09, 0.64 +/- 0.34, and 0.60 +/- 0.17 at 120 min, respectively. The tumor-to-organ ratios obtained with three radiopharmaceuticals, especially with blood, heart, lung, muscle, and brain were high and these ratios increased with time. The tumor-to-organ ratios obtained with 18F-5-FdUR were always 1.3-4 times higher than 18F-5-FU and 18F-5-FUR. We concluded that 18F-5-FdUR was a suitable radiopharmaceutical for tumor imaging. Positron emission tomography of a rabbit tumor located on the chest with 18F-5-FdUR clearly showed the tumor within 1 h.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6223818     DOI: 10.1007/bf00522517

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  6 in total

1.  Tumor uptake of radiolabeled pyrimidine bases and pyrimidine nucleosides in animal models--II. 6-[3H]-5-fluoro-2'-deoxyuridine.

Authors:  D N Abrams; E E Knaus; B C Lentle; L I Wiebe
Journal:  Int J Nucl Med Biol       Date:  1979

2.  STUDIES WITH RADIOACTIVE DI-AZO DYES. III. THE DISTRIBUTON OF RADIOACTIVE DYES IN TUMOR-BEARING MICE.

Authors:  F D Moore; L H Tobin; J C Aub
Journal:  J Clin Invest       Date:  1943-03       Impact factor: 14.808

3.  Distribution of 18F-5-fluorouracil in tumor-bearing mice and rats.

Authors:  J Shani; W Wolf; T Schlesinger; H L Atkins; P R Bradley-Moore; V Casella; J S Fowler; D Greenberg; T Ido; R M Lambrecht; R MacGregor; C Mantescu; R Neirinckx; P Som; A P Wolf; I Wodinsky; K Meaney
Journal:  Int J Nucl Med Biol       Date:  1978-03

4.  The synthesis of 18 F-5-fluorouracil. VII.

Authors:  J S Fowler; R D Finn; R M Lambrecht; A P Wolf
Journal:  J Nucl Med       Date:  1973-01       Impact factor: 10.057

5.  Dosimetry and preliminary human studies of 18F-5-fluorouracil.

Authors:  J Shani; D Young; T Schlesinger; J K Siemsen; R T Chlebowski; J R Bateman; W Wolf
Journal:  Int J Nucl Med Biol       Date:  1982

6.  Tracer studies of potential radiosensitizing agents: tetrasodium 2-14C-methyl-1:4-naphthohydroquinone diphosphate.

Authors:  D H MARRIAN; D R MAXWELL
Journal:  Br J Cancer       Date:  1956-09       Impact factor: 7.640

  6 in total
  10 in total

Review 1.  Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.

Authors:  D A Mankoff; F Dehdashti; A F Shields
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

2.  (99m)Tc-EC-guanine: synthesis, biodistribution, and tumor imaging in animals.

Authors:  David J Yang; Kaoru Ozaki; Chang-Sok Oh; Ali Azhdarinia; Thomas Yang; Megumi Ito; Allison Greenwell; Jerry Bryant; Saady Kohanim; Vincenzo K Wong; E Edmund Kim
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

3.  Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose.

Authors:  G W Visser; G C Gorree; G J Peters; J D Herscheid
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Studies on 18F-labeled pyrimidines. II. Metabolic investigation of 18F-5-fluorouracil, 18F-5-fluoro-2'-deoxyuridine and 18F-5-fluorouridine in rats.

Authors:  K Ishiwata; T Ido; K Kawashima; M Murakami; T Takahashi
Journal:  Eur J Nucl Med       Date:  1984

5.  Brain tumor accumulation and plasma pharmacokinetic parameters of 2'-deoxy-5-18F-fluorouridine.

Authors:  K Ishiwata; Y Tsurumi; M Kameyama; K Sato; R Iwata; T Takahashi; T Ido; T Yoshimoto
Journal:  Ann Nucl Med       Date:  1993-08       Impact factor: 2.668

6.  Metabolic changes of glioma following chemotherapy: an experimental study using four PET tracers.

Authors:  K Sato; M Kameyama; K Ishiwata; R Katakura; T Yoshimoto
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

7.  Studies on 18F-labeled pyrimidines III. Biochemical investigation of 18F-labeled pyrimidines and comparison with 3H-deoxythymidine in tumor-bearing rats and mice.

Authors:  K Ishiwata; T Ido; Y Abe; T Matsuzawa; M Murakami
Journal:  Eur J Nucl Med       Date:  1985

8.  Clinical application of 18F-FUdR in glioma patients--PET study of nucleic acid metabolism.

Authors:  M Kameyama; K Ishiwata; Y Tsurumi; J Itoh; K Sato; R Katakura; T Yoshimoto; J Hatazawa; M Ito; T Ido
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma.

Authors:  Samuele Cazzamalli; Alberto Dal Corso; Dario Neri
Journal:  Mol Cancer Ther       Date:  2016-09-08       Impact factor: 6.261

10.  Differential diagnosis of AH109A tumor and inflammation by radioscintigraphy with L-[methyl-11C]methionine.

Authors:  K Kubota; T Matsuzawa; T Fujiwara; T Sato; M Tada; T Ido; K Ishiwata
Journal:  Jpn J Cancer Res       Date:  1989-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.